paramethasone acetate
Trade name: haldrone
Small moleculeapproved
Approved
Apr 17, 1961
Paramethasone acetate (a derivative of paramethasone) is a glucocorticoid with the general properties of corticosteroids. It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
Indications
Approved for
Mechanism of action
- Glucocorticoid receptorAGONIST
NR3C1 agonist
Approval history
- approvedApr 17, 1961
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O- Mol. weight
- 434.4977 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaParamethasone acetate ↗
- NCATS8X50N88ZDP ↗
- ChEMBLCHEMBL1579 ↗
- ChEMBLCHEMBL1200342 ↗
Also known as
- cortiden
- dillar
- dillar
- flumethone
- haldrone
- haldrone
- haldrone
- monocortin
- paramethasone
- paramethasone
- paramethasone
- paramethasone
- paramethasone acetate
- paramethasone acetate
- paramethasone acetate
- paramethasone acetate
- paramethasone acetate
- paramethasone acetate
- paramethasone acetate
- paramethasone acetate
- paramethasone acetate
- paramezone